PolyNovo Limited (ASX:PNV)

Market Cap	659.76M -37.4%
Revenue (ttm)	149.85M +16.4%
Net Income	7.34M -44.4%
EPS	0.01 -44.4%
Shares Out	690.84M
PE Ratio	90.95
Forward PE	62.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,549,648
Open	0.9600
Previous Close	0.9550
Day's Range	0.9350 - 0.9700
52-Week Range	0.8100 - 1.6600
Beta	1.36
Analysts	Buy
Price Target	1.25 (+32.28%)
Earnings Date	Aug 26, 2026

About PolyNovo

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, Hong Kong, and China. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn; NovoSorb MTX for burns, chronic, trauma, and surgical wounds; and hernia repair, plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 301
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PNV

Financial Performance

In fiscal year 2026, PolyNovo's revenue was 149.85 million, an increase of 16.43% compared to the previous year's 128.70 million. Earnings were 7.34 million, a decrease of -44.45%.

Analyst Summary

According to 8 analysts, the average rating for PNV stock is "Buy." The 12-month stock price target is $1.25, which is an increase of 32.28% from the latest price.

Price Target

$1.25

(32.28% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 17, 2026

Data Sources Report a data error